Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism
Amicus Therapeutics (Nasdaq: FOLD) announced its participation in the 14th International Congress of Inborn Errors of Metabolism from November 21-23, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) announced its participation in the 14th International Congress of Inborn Errors of Metabolism from November 21-23, 2021. The company is presenting two digital posters: one on the long-term efficacy of migalastat in patients with amenable GLA variants and another on the incidence of Fabry disease in children. Both presentations highlight key findings relevant to the treatment of rare metabolic diseases. Interested parties can access these presentations through the Investors section of the Amicus website.
Positive
- Presentation of research findings at a prominent international congress enhances Amicus's credibility and visibility in the biotech field.
- Focus on migalastat shows ongoing commitment to advancing treatments for rare diseases, potentially attracting investor interest.
Negative
- None.
Details
News Market Reaction – FOLD
The recorded move for FOLD in the trading session of this news was -0.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters for presentation at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) being held virtually and in Sydney, Australia, November 21-23, 2021.
Digital Poster Presentations:
- Long-term multisystemic efficacy with migalastat in ERT-naïve and ERT-experienced patients with amenable GLA variants
- Presenter: Drago Bratkovic, MD, PARC Research Clinic, Adelaide, Australia
- Incidence and prevalence of newborn, paediatric, and adolescent patients with Fabry disease: a targeted literature review
- Presenter: Ian Keyzor, Amicus Therapeutics, Marlow, United Kingdom
The posters can be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com.
For more information on the International Congress of Inborn Errors of Metabolism 2021, please visit www.iciem2021.com.au.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.
CONTACT:
Investors:
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Diana Moore
Head of Global Corporate Affairs & Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.